pentobarbital will reduce the extent or effect of cobimetinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Steer clear of coadministration. Robust or average CYP3A inducers may possibly minimize cobimetinib systemic exposure by >80% and lower its efficacy.pentobarbital will reduce the level or result of cevimeline by a